Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Carla Minoia(Istituto Tumori Bari), Annalisa Saracino(University of Bari Aldo Moro), Davide Fiore Bavaro(Humanitas University), Lucia Diella(Humanitas University), Pellegrino Musto(University of Bari Aldo Moro), Valentina Totaro(University of Bari Aldo Moro), Attilio Guarini(Istituto Tumori Bari), Giacomo Loseto(Istituto Tumori Bari), Michele Camporeale(University of Bari Aldo Moro), Carmen Pelligrino(University of Bari Aldo Moro), Tommasina Perrone, Crescenza Pasciolla(Istituto Tumori Bari), Francesco Di Gennaro(University of Bari Aldo Moro), Immacolata Attolico(Ospedale San Carlo), Felice Clemente(Istituto Tumori Bari), Vito Spada(University of Bari Aldo Moro)
Blood
November 15, 2022
10.1182/blood-2022-168809
Cited by 0

Related Papers

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
|Blood|2011|268
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
|Journal of Clinical Oncology|2010|268